Description du projet
Un traitement combiné pour lutter contre les maladies inflammatoires à médiation immunitaire
Les maladies inflammatoires à médiation immunitaire (MIMI) représentent un groupe de troubles auto-immunitaires hétérogènes partageant certaines caractéristiques communes à un niveau cellulaire et moléculaire; l’arthrite rhumatoïde, le psoriasis, la maladie de Crohn, la colite ulcéreuse et le lupus érythémateux disséminé en font partie. Le projet DocTIS, financé par l’UE, entend améliorer considérablement le pronostic des MIMI en identifiant des traitements combinés efficaces et les groupes de patients qui présentent une réponse optimale au traitement. En utilisant des échantillons issus de biobanques spécialisées dans les MIMI, les nouvelles données moléculaires seront obtenues à l’aide de technologies avancées à haut débit. Des méthodes de biologie des systèmes serviront à modéliser les réponses aux traitements ciblés et à prédire quelles combinaisons médicamenteuses agiront en synergie. Pour fournir une validation du principe, après la phase préclinique, le traitement combiné optimal sera testé chez un groupe de patients ayant un profil de biomarqueur positif.
Objectif
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of common autoimmune diseases that include clinically heterogeneous disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus. Despite their clinical heterogeneity, IMIDs share a significant number of features at the molecular and cellular levels. Recently developed therapies targeting common key molecules of the immune system like anti-TNF agents, have collectively resulted in a significant improvement in the management of IMIDs. Still, the complete control of the chronic inflammatory process is rarely attained, and too many patients experience a poor response, if at all. This inefficacy has become a major economic burden and severely impacts on the wellbeing of many European citizens. The DocTIS projects aims to profoundly change this trend by identifying highly effective combinatorial therapies as well as the group of patients where this response will be optimal. Using the standardized samples from one of the world’s largest biobanks specialized in IMIDs, new molecular data will be generated using advanced high-throughput technologies including single cell RNA-seq. Systems biology methods will be applied to this unique clinical and molecular data to model the response to targeted therapies and predict what drug combinations will act synergistically and on which types of patients. After validation in a preclinical stage, the optimal combinatorial therapy will be tested in a group of patients with a positive biomarker profile. Using a basket trial, a new type of clinical trial design that incorporates molecular marker information, the DocTIS project will provide proof of concept of the utility of combinatorial therapy and personalized medicine for the effective control of disease activity in IMIDs.
Champ scientifique
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health scienceshealth sciencespersonalized medicine
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
08035 Barcelona
Espagne